

**Jan-Anders Karlsson, PhD, Chief Executive Officer, Verona Pharma plc**

Dr. Karlsson has been CEO and a director of Verona Pharma since June 2012. He has over 30 years of experience in the pharmaceutical industry, with many successes in the drug discovery and development areas in both large pharmaceutical and biotech companies where he built entrepreneurial drug discovery and development cultures. Before joining Verona Pharma, Jan-Anders was the CEO of S\*BIO Pte Ltd in Singapore from 2005, which discovered 6 novel drug candidates and brought the lead JAK2 inhibitor pacritinib to phase 3 and the HDAC inhibitor pracinostat to phase 2, raised venture funding and established multiple international drug-development and commercial partnerships. Prior to joining S\*BIO, Jan-Anders was the Executive Vice President, Global Research of Bayer Pharma, where he was a member of the Executive Management Committee and responsible for the company's global drug discovery organization. He worked with Bayer from 1996 and before this he held management positions with increasing responsibility in Rhone-Poulenc Rorer from 1990 to 1996 and Astra AB from 1979 to 1990.